FOR PLUS PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of FOR PLUS PHARMA is 3.4% (moderate). The 2025 annual accounts show equity of €99,809 and a net result of €82,647. Equity is shrinking by about 27% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 38% of 13,605 sector peers (NACE 46, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
22-09
NBB filing
Annual accounts filed
financial year 2025 · micro format · 53 days late
2025
19-09
NBB filing
Annual accounts filed
financial year 2024 · micro format · 50 days late
16-05
NBB filing
Annual accounts filed
financial year 2023 · micro format · 289 days late
2024
31-12
Financial
Back to profitnet €1,200
Net result €1,200 after 3 loss-making years.
2023
31-12
Financial
Weakest financial yearnet -€49,251
Net result drops to -€49,251, the lowest in the series; recovery starts the following year.
13-11
NBB filing
Annual accounts filed
financial year 2022 · micro format · 105 days late
05-01
NBB filing
Annual accounts filed
financial year 2021 · micro format · 158 days late
2022
23-12
NBB filing
Annual accounts filed
financial year 2020 · micro format · 510 days late
25-11
Bankruptcy
Judicial dissolution and immediate closure
Enterprise Court of Hainaut, Mons division · judgment of 21-11-2022
SignalFinancial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 5 deeds read
About the unread acts
We know of 5 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.